Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Katherine Fornell, age 5, from suburban Chicago, receives her first dose of the COVID-19 vaccine during the first week it became available in the U.S. The FDA authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine Oct. 29 for the prevention of COVID-19 in children 5 to 11 years of age. This was based on a safety review of more than 3,000 patients receiving the vaccine ages 5-11.

Feature | Coronavirus (COVID-19)

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Children Ages 5-11

November 5, 2021 — The U.S. Food and Drug Administration (FDA) authorized the emergency use of the Pfizer-BioNTech COVID ...

November 05, 2021

Feature | Pharmaceuticals | By Dave Fornell, DAIC Editor

Draft Recommendations Suggest Not Using Aspirin for Prevention in Many Patients

There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart ...

October 13, 2021

$FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).$

News | Pharmaceuticals

FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

October 07, 2021

$A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line at the European Society of Cardiology (ESC) 2021 Congress, and was published in the New England Journal of Medicine. Data from the EMPEROR-Preserved and in EMPEROR-Reduced trials.$

News | Heart Failure

Empagliflozin Benefits Heart Failure Patients With Reduced and Preserved Ejection Fraction

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

October 04, 2021

News | Coronavirus (COVID-19)

COVID Long-hauler Symptoms May be Caused by Antibody Attacks on ACE2

September 28, 2021 — A research team at the University of Arkansas for Medical Sciences (UAMS) has identified a ...

September 28, 2021

Results of the STROKE-VT trial showed direct oral anticoagulants (DOACs) are more effective than aspirin in reducing cerebrovascular events, including stroke in patients undergoing ventricular tachycardia ablation.

News | EP Lab

Oral Anticoagulants After Catheter Ablation Helps Reduce Stroke in High-Risk Patients

July 29, 2021 – Results of the STROKE-VT trial shows direct oral anticoagulants (DOACs) are more effective than aspirin ...

July 29, 2021

A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19.

News | Coronavirus (COVID-19)

Large Study Confirms Statins Reduce COVID-19 Severity

July 21, 2021 — In a new study from University of California San Diego School of Medicine, researchers have confirmed ...

July 21, 2021

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.

News | Stents

FDA Clears Xience Stent for One Month DAPT in High Risk Bleeding Patients

June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...

June 30, 2021

Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

News | Coronavirus (COVID-19)

Study Provides MIS-C Treatment Guidance To Avoid Cardiovascular Dysfunction

June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in children ...

June 28, 2021

News | Antiplatelet and Anticoagulation Therapies

FDA Clears Pradaxa as First Oral Anticoagulant for Children

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

June 21, 2021

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

News | Heart Failure

GALACTIC-HF Shows Omecamtiv Mecarbil Brings Greater Benefits for Severe Heart Failure

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

May 18, 2021

News | Coronavirus (COVID-19)

Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

May 18, 2021

The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

May 17, 2021

Etripamil nasal spray was shown in a post-hoc analysis to resolve paroxysmal supraventricular tachycardia faster and more completely than placebo in most patients and reduced the number of emergency room visits for additional interventions.

Feature | EP Lab | By Dave Fornell, Editor

Etripamil Nasal Spray Reduced ER Vistsis and More PSVT Resolution in New NODE-301 Analysis

May 16, 2020 — New data from in the NODE-301 Trial for the patient-administered nasal spray etripamil to resolve ...

May 16, 2021

The mechanism of action for mavacamten, a cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (oHCM). EXPLORER-HCM trial #ACC21 #ACC2021

News | Pharmaceuticals

Mavacamten Is Effective in Treating Obstructive Hypertrophic Cardiomyopathy

May 15, 2021 — A new analysis of the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in ...

May 15, 2021